title: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.
abstract: Malignant hyperthermia (MH) is a potentially lethal condition in which sustained muscle contracture, with attendant hypercatabolic reactions and elevation in body temperature, are triggered by commonly used inhalational anaesthetics and skeletal muscle relaxants. In humans, the trait is usually inherited in an autosomal dominant fashion, but in halothane-sensitive pigs with a similar phenotype, inheritance of the disease is autosomal recessive or co-dominant. A simple and accurate non-invasive test for the gene is not available and predisposition to the disease is currently determined through a halothane- and/or caffeine-induced contracture test on a skeletal muscle biopsy. Because Ca2+ is the chief regulator of muscle contraction and metabolism, the primary defect in MH is believed to lie in Ca2+ regulation. Indeed, several studies indicate a defect in the Ca2+ release channel of the sarcoplasmic reticulum, making it a prime candidate for the altered gene product in predisposed individuals. We have recently cloned complementary DNA and genomic DNA encoding the human ryanodine receptor (the Ca2(+)-release channel of the sarcoplasmic reticulum) and mapped the ryanodine receptor gene (RYR) to region q13.1 of human chromosome 19 (ref. 14), in close proximity to genetic markers that have been shown to map near the MH susceptibility locus in humans and the halothane-sensitive gene in pigs. As a more definitive test of whether the RYR gene is a candidate gene for the human MH phenotype, we have carried out a linkage study with MH families to determine whether the MH phenotype segregates with chromosome 19q markers, including markers in the RYR gene. Co-segregation of MH with RYR markers, resulting in a lod score of 4.20 at a linkage distance of zero centimorgans, indicates that MH is likely to be caused by mutations in the RYR gene.
authors.affiliation: Banting and Best Department of Medical Research, Charles H. Best Institute, University of Toronto, Ontario, Canada.
authors.forename: D H
authors.initials: DH
authors.lastname: MacLennan
authors.forename: C
authors.initials: C
authors.lastname: Duff
authors.forename: F
authors.initials: F
authors.lastname: Zorzato
authors.forename: J
authors.initials: J
authors.lastname: Fujii
authors.forename: M
authors.initials: M
authors.lastname: Phillips
authors.forename: R G
authors.initials: RG
authors.lastname: Korneluk
authors.forename: W
authors.initials: W
authors.lastname: Frodis
authors.forename: B A
authors.initials: BA
authors.lastname: Britt
authors.forename: R G
authors.initials: RG
authors.lastname: Worton
mesh_terms: D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D002888:Chromosomes, Human, Pair 19; D005260:Female; D008040:Genetic Linkage; D006221:Halothane / Q000494:pharmacology; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008126:Lod Score; D008297:Male; D008305:Malignant Hyperthermia / Q000235:genetics*; D009119:Muscle Contraction / Q000187:drug effects; D009154:Mutation; D010375:Pedigree; D012150:Polymorphism, Restriction Fragment Length; D011950:Receptors, Cholinergic / Q000235:genetics*; D019837:Ryanodine Receptor Calcium Release Channel; D013552:Swine / Q000235:genetics
chemical_list: D011950:Receptors, Cholinergic; D019837:Ryanodine Receptor Calcium Release Channel; D002110:Caffeine; D006221:Halothane